FDA approves tough-to-abuse formulation of oxycodone

FDA approves tough-to-abuse formulation of oxycodone
Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other therapies are ineffective or unavailable.

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other therapies are ineffective or unavailable.

Targiniq ER has properties that are designed to deter abuse of the drug by snorting or injection, the FDA said in a news release. It contains naloxone, designed to block the euphoric effects of oxycodone, the agency said. Targiniq ER can still be abused by taking too many pills, the FDA warned, stressing that an overdose could cause death. The drug is not meant for as-needed pain relief, the agency said, repeating its warning of the potential for abuse and addiction.

Targiniq ER was evaluated in a clinical study of 601 people with chronic lower back . The most common side effects were nausea and vomiting.

The agency said it is requiring the manufacturer to conduct additional post-marketing studies to assess the drug's risks of misuse, addiction, and abuse.

Targiniq ER is manufactured by Purdue Pharma, based in Stamford, Conn.

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

Sivextro approved for adult skin infections

Jun 23, 2014

(HealthDay)—The antibiotic Sivextro (tedizolid phosphate) has been approved by the U.S. Food and Drug Administration to treat adults with skin infections.

FDA encourages opioid prescribers to pursue training

Mar 12, 2013

(HealthDay)—Prescribers of extended-release/long-acting (ER/LA) opioid analgesics are encouraged to participate in continuing medical education (CME) provided by manufacturers of these analgesics, according ...

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

13 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments